CXCL8 and neoplasm: NE abrogates the tumor-suppressing effect of anti-angiogenic agent sunitinib by activating β-adrenoceptor (ADRB)-cAMP-PKA signaling pathway to increase the expression of vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) [43].